The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.
The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.
